Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
BACKGROUND
The production of oxidative stress as a result of postprandial hyperglycaemia is now recognized as an important contributing factor in the development of diabetes complications. The objective of this study was to examine the effects of pramlintide on plasma concentrations of glucose and several markers of oxidative stress in patients with type 2 diabetes following a standardized meal.


METHODS
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States. A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study. Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days. Plasma concentrations of glucose, nitrotyrosine (NT), oxidized-LDL cholesterol (OxLDL-C), and total radical trapping parameter (TRAP) were assessed during the 4-h postprandial period.


RESULTS
Compared to placebo, pramlintide treatment reduced postprandial excursions of glucose, NT, and OxLDL-C and protected TRAP from consumption. Correlation analysis revealed positive associations between placebo-corrected glucose incremental AUC(0-4 h) and both NT and OxLDL-C and a negative association between placebo-corrected glucose incremental AUC(0-4h) and TRAP.


CONCLUSIONS
The reduction in postprandial glucose excursions achieved with addition of pramlintide to rapid-acting insulin in type 2 diabetes was associated with a reduction in postprandial markers of oxidative stress.
Ceriello
Antonio
A
Warwick Medical School, Coventry, UK.
Lush
Cameron W
CW
Darsow
Tamara
T
Piconi
Ludovica
L
Corgnali
Maddelena
M
Nanayakkara
Nuwan
N
Frias
Juan P
JP
Maggs
David
D
D000293:Adolescent; D000328:Adult; D000682:Amyloid / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives / Q000627:therapeutic use; D061268:Insulin Lispro; D058228:Islet Amyloid Polypeptide; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D019518:Postprandial Period / Q000502:physiology*; D016037:Single-Blind Method; D014443:Tyrosine / Q000031:analogs & derivatives / Q000097:blood
D000682:Amyloid; D015415:Biomarkers; D001786:Blood Glucose; D008078:Cholesterol, LDL; D007328:Insulin; D061268:Insulin Lispro; D058228:Islet Amyloid Polypeptide; C002744:3-nitrotyrosine; D014443:Tyrosine; C105254:pramlintide